NEWARK, CA / ACCESS Newswire / February 21, 2025 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or "the Company") today reported financial results for the fourth quarter and full year ended ...

Ex-Takeda VP Tauhid Ali, Ph.D., with broad leadership and drug development experience becomes Board DirectorSeasoned regulatory strategist Darren ...

Maternal health in pregnancy is associated with offspring autism, and these associations are largely attributed to familial ...

CEOs emphasize the need to stay nimble and rethink supply chains as barriers to trade are erected in an increasingly ...

Researchers identify a new player in human immunity that can go rogue and turn the immune system against the body’s own ...

In the past week, a Boston biotech led by longtime industry CEO Harvey Berger said it plans to shut down, while another ...

Patients with celiac disease have double the incidence rate of chronic liver disease compared with those without this ...

International biotechnology company GlaxoSmithKline is moving its vaccine and infectious disease research teams to Cambridge, ...

During a live event, Alexander I. Spira, MD, PhD, and participants NGS testing practices and the rationale behind their ...

Explore AC Immune's innovative Alzheimer's and Parkinson's therapies, key pharma collaborations, and financial outlook. Learn more on ACIU stock here.

Nanoparticle characterization is vital for mRNA vaccine efficacy, ensuring safety and regulatory compliance in the ...

Children with avoidant restrictive food intake disorder (ARFID) have an elevated risk of developing psychiatric and physical conditions, a new study from Karolinska Institutet published in JAMA ...